APLS - CIK 0001492422
Apellis Pharmaceuticals, Inc. (APLS) reported net income of $22.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $22.39M | +111.3% |
| FY 2024 | -$197.88M | +62.6% |
| FY 2023 | -$528.63M | +18.9% |
| FY 2022 | -$652.17M | +12.6% |
| FY 2021 | -$746.35M | -116.4% |
| FY 2020 | -$344.87M | -13.2% |
| FY 2019 | -$304.71M | -139.0% |
| FY 2018 | -$127.50M | -150.0% |
| FY 2017 |
Apellis Pharmaceuticals, Inc. (APLS) reported net income of $22.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Apellis Pharmaceuticals, Inc.'s net income grew from -$46.52M to $22.39M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$51.01M |
| -88.0% |
| FY 2016 | -$27.12M | +41.7% |
| FY 2015 | -$46.52M | - |